TUCSON, Ariz., April 17, 2024 — Critical Path Institute (C-Path) today announced the appointment of Amanda Klein, Pharm.D., as Executive Director for its two newest public-private partnerships: the Critical Path for Lysosomal Diseases (CPLD) and the Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1) consortia . Klein brings a wealth of experience, having previously served as Executive Director of C-Path’s Transplant Therapeutics Consortium (TTC), where she orchestrated successful composite biomarker qualification submissions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency.Continue reading
Author Archive: Roxan Olivas
World Parkinson’s Day Impact Story: C-Path’s Critical Path for Parkinson’s Consortium
Active Lifestyles Key for Parkinson’s Advocates Zenner-Dolan, Kwok as They Await Advancements in Treatments
By Alexander Diegel
C-Path Announces New Board Members Bonnie A. Allin and Louis Breton
Allin and Breton join C-Path Board of Directors to support strategic visionContinue reading
C-Path Launches Clinical Trial Simulator for Duchenne Muscular Dystrophy Research
TUCSON, Ariz., March 28, 2024 — Critical Path Institute’s (C-Path) Duchenne Regulatory Science Consortium (D-RSC) is excited to announce the launch of a groundbreaking model-based Clinical Trial Simulator (CTS), specifically designed to improve design of efficacy studies for potential therapies for Duchenne muscular dystrophy (DMD). This pioneering Drug Development Tool is set to positively impact the medical research community by significantly optimizing clinical trial design.Continue reading
C-Path Announces New Executive Directors for Duchenne Regulatory Science Consortium and T1D Consortium
Appointments of Seasoned Researchers Reinforce C-Path’s Leadership in Accelerating Innovative Therapy DevelopmentContinue reading
C-Path, ActiGraph, and University of Canberra Collaborate to Generate Evidence to Support Regulatory Qualification of Novel Digital Health Technology Measures in Chronic Heart Failure
Collaboration will generate evidence to contribute to FDA qualification of a patient-centered, accelerometer-based clinical outcome assessment in CHFContinue reading
C-Path Promotes Cécile Ollivier to Vice President of Global Affairs, Expanding Leadership in Drug Development
Ollivier to steer global strategic initiatives, reinforcing C-Path’s commitment to accelerating medical innovation and regulatory science.Continue reading
C-Path’s TRxA Announces its 2024 Global Request for Proposals from Academic Investigators Working to Advance Drug Development Projects
NEW FUNDING OPPORTUNITY!
TUCSON, Ariz, January 22, 2024 – Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) today announced its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants, also known as BRIDGe. Continue reading